- Brand-name Wegovy®, Ozempic® and Zepbound® are FDA-approved and made by Novo Nordisk and Lilly. Compounded versions are made by licensed pharmacies and are not FDA-approved.
- Compounded is much cheaper: roughly $99 to $300 a month including the clinician, against $299 to $449 for the brand-name medication alone.
- The rules have tightened. Since the shortages ended in 2025, pharmacies may compound these drugs mainly when a prescriber documents a clinical reason for that patient, and FDA stepped up enforcement in 2026.
- If you choose compounded, choose carefully: a real clinician, a named licensed pharmacy, dosing explained in milligrams and syringe units, and no claims that it is "the same as" Wegovy® or Zepbound®.
What "compounded" means
A compounded medication is made by a pharmacy, rather than mass-produced by the company that developed and tested it. Pharmacies have long compounded medicines for patients who need something the approved product cannot offer, such as a different strength or a version without an ingredient they are allergic to.
There are two kinds of compounder 1:
- 503A pharmacies are state-licensed pharmacies that compound for an individual patient against a prescription. Most compounded GLP-1s sold through telehealth come from these.
- 503B outsourcing facilities are registered with FDA and can make larger batches, but only from ingredients on an approved list or for drugs in shortage.
Neither kind of product is FDA-approved, and FDA does not approve or license pharmacies, so an "FDA-approved pharmacy" does not exist 23. Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities are also inspected by FDA.
Why compounded GLP-1s became so common
When demand for Wegovy®, Ozempic®, Mounjaro® and Zepbound® outstripped supply in 2022 to 2024, the drugs went on FDA's shortage list. Federal law lets compounders make copies of drugs in shortage, and they did, in very large volumes, at a fraction of the brand-name price. A whole telehealth industry grew up around it.
The shortages then ended. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025, with grace periods for compounders running out between February and May 2025 1. Courts declined to block those decisions.
What the rules allow now
With the shortages over, compounders may not routinely make what FDA calls "essentially copies" of the approved drugs: the same ingredient, at a similar strength, by the same route 1. Two exceptions remain:
- A documented clinical difference. A 503A pharmacy can compound a version for a named patient when the prescriber decides, and records, that a change makes a significant clinical difference for that person. FDA has said that adding vitamin B12 or a similar ingredient does not, on its own, make a product different 1.
- Very low volume. FDA does not intend to act against a pharmacy making four or fewer prescriptions of an essentially-copy product in a month 1.
In 2026 FDA made clear it intends to enforce these limits. In February it announced action against mass-marketed compounded "alternatives", and in March it sent warning letters to 30 telehealth companies over claims that implied their products were the same as the approved drugs and over selling compounded products without saying who made them 45. In April it proposed permanently barring outsourcing facilities from using bulk semaglutide, tirzepatide and liraglutide 6. Some large companies changed course: Hims & Hers, for example, moved its weight loss business to brand-name medication and kept compounded versions for personalised dosing only 11.
Compounded GLP-1s are still prescribed and dispensed legally by licensed clinicians and pharmacies, but the industry is under more scrutiny than at any time since it began. A provider's approach to these rules is now a fair test of how carefully it is run.
Compounded vs brand-name, side by side
| Brand-name (Wegovy®, Zepbound®) | Compounded semaglutide or tirzepatide | |
|---|---|---|
| FDA-approved | Yes | No |
| Who makes it | Novo Nordisk or Lilly | A state-licensed compounding pharmacy |
| Evidence for results | Large trials: about 15% average weight loss for semaglutide and about 21% for tirzepatide at the top dose 8 | No large trials of compounded versions |
| Typical form | Prefilled pens or pills; Zepbound® also in vials | Multi-dose vials drawn with a syringe |
| Typical monthly cost | $299 to $449 for the medication alone, self-pay 910 | About $99 to $300, usually including the clinician |
| Insurance and Medicare | Sometimes covered; Medicare $50 Bridge for eligible members | Not covered; cash-pay, often HSA or FSA eligible |
The safety concerns, plainly
FDA's concerns about compounded GLP-1s are specific, and most of them are things you can guard against 2:
- Dosing errors. Vials are measured by syringe, and doses get confused between milligrams, millilitres and the "units" printed on insulin syringes. Some people have been hospitalized after taking several times their intended dose 7. You should be told your dose in both milligrams and syringe units, and be given the right syringes.
- The wrong ingredient. Semaglutide sodium and semaglutide acetate are salt forms that FDA regards as different active ingredients, with no lawful basis for compounding 2.
- Doses and schedules beyond the label. FDA has reports of compounded products given at higher doses or increased faster than the approved schedules, causing stomach side effects 2.
- Handling. Throw a multi-dose vial away 28 days after first use, and do not use an injectable that arrives warm 2.
- Counterfeits. FDA has seen fake labels naming pharmacies that do not exist, and illegal "research use only" products sold online 2.
- Under-reporting. FDA had received about 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide by May 2026, and says the real number is likely higher because 503A pharmacies are not required to report them 2.
How to choose a compounded provider: a checklist
- A clinician licensed in your state reviews your health history before anything is prescribed, and stays available for questions and dose changes.
- You can find out which pharmacy makes your medication, and check its licence on your state board of pharmacy's website.
- The medication is semaglutide or tirzepatide base, not a salt form. Ask if it is not stated.
- Your dose is given in milligrams and in syringe units, with the right syringes and clear instructions.
- It ships cold and the provider tells you what to do if it arrives warm.
- No claims that it is "generic", "the same as" or "identical to" Wegovy® or Zepbound®, and no "FDA-approved pharmacy". Those are claims FDA has said are misleading 34.
- The ongoing price is shown before you pay, along with the refund and cancellation terms.
- The dosing follows a gradual schedule similar to the approved products', not a rush to high doses.
Our #1 pick, TotalRx, prescribes compounded semaglutide and tirzepatide through licensed US clinicians and state-licensed pharmacies, shows its renewal price before checkout, and is $129 a month for semaglutide on a 12-month plan. Its clinicians can also prescribe brand-name medication if you prefer it.
When brand-name is the better choice
- Your insurance covers it, or you have commercial insurance and can use a savings card.
- You are on Medicare and qualify for the $50 GLP-1 Bridge.
- You want a pill. The Wegovy® pill and Foundayo® are brand-name only.
- You want the product that was tested in the trials, in a prefilled pen, and the extra cost is manageable for you.
For prices of every brand-name option, see what GLP-1s cost without insurance.
Questions and answers
Is compounded semaglutide the same as Wegovy or Ozempic?
No. It contains the same active ingredient but it is not an FDA-approved product, it is made by a different manufacturer to a different process, and it has not been through FDA review for safety, effectiveness or quality. FDA has warned companies not to describe compounded GLP-1s as generic or the same as the approved drugs.
Is compounded tirzepatide legal in 2026?
Compounding is legal, but the room for it has narrowed. Since FDA declared the tirzepatide shortage over in December 2024 and the grace periods ended in early 2025, pharmacies may not routinely make copies of Zepbound®. A licensed pharmacy can still compound for an individual patient when the prescriber decides a change makes a significant clinical difference for that person, and FDA has been taking action against companies it considers to be stretching that rule.
Is compounded semaglutide safe?
It can be made safely by a reputable licensed pharmacy, but it carries extra risks the approved products do not, because it is not reviewed by FDA. FDA has received hundreds of adverse event reports, including dosing errors from measuring doses out of vials, and has warned about products made with semaglutide salts, which are a different ingredient.
Why is compounded semaglutide so much cheaper?
Compounding pharmacies do not carry the research, trial and brand costs of the manufacturers, and many sell medication in multi-dose vials rather than pens. Brand-name prices have also fallen, so the gap is smaller than it was, but it is still large.
Does compounded semaglutide work as well as Wegovy?
The large trials that showed about 15% average weight loss were of brand-name Wegovy®. There are no comparable large trials of compounded versions, so their results cannot be assumed to be identical.
What are semaglutide sodium and semaglutide acetate?
They are salt forms of semaglutide, which FDA says are different active ingredients from the one in the approved drugs. FDA knows of no lawful basis for compounding with them. Ask your provider which form your medication contains.
Can I switch from compounded to brand-name later?
Yes. A clinician will usually set a starting point on the brand-name product's own dosing schedule rather than converting your compounded dose exactly. See our guide to switching.
Keep reading
Sources
- FDA: clarifies policies for compounders as national GLP-1 supply begins to stabilize (current as of April 1, 2026)
- FDA: concerns with unapproved GLP-1 drugs used for weight loss (updated October 1, 2026)
- FDA: what telehealth companies should know when promoting compounded drugs
- FDA: intends to take action against non-FDA-approved GLP-1 drugs (February 6, 2026)
- FDA: warns 30 telehealth companies against illegal marketing of compounded GLP-1s (March 3, 2026)
- FDA: proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
- FDA: dosing errors associated with compounded semaglutide (July 26, 2024)
- Wilding et al., Once-weekly semaglutide in adults with overweight or obesity (STEP 1), NEJM 2021
- Eli Lilly: Zepbound® self-pay prices
- NovoCare Pharmacy: Wegovy® self-pay prices
- Hims & Hers: strategic shift for its US weight loss business (2026)
How we write our guides. We read the manufacturers' prescribing information, FDA and other official sources, published trials and each provider's own pricing and policies, and link to them so you can check our work. Figures were correct when we last checked them on October 19, 2026; prices and rules change often, so confirm them before you act. Medical disclaimer. This guide is general information, not medical advice, and no one at ProviderCompare is your clinician. Talk to a licensed healthcare professional before starting, changing or stopping any medication. Compounded GLP-1 medications are not FDA-approved and do not undergo FDA review for safety, effectiveness or quality. Brand names are trademarks of their owners, used for identification only.